Precision Therapy Based on Immune Microenvironment by Transcriptome Sequencing of Osteosarcoma, a Prospective, Multi-cohort Exploratory Clinical Study

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06776198

Acronym

PTMTO

Enrollment

100

Registered

2025-01-15

Start date

2025-03-01

Completion date

2027-06-01

Last updated

2025-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteosarcoma, Precision Medicine, Transcriptome, Tumor Microenvironment

Keywords

osteosarcoma, transcriptome, tumor microenviroment, precision medicine

Brief summary

Bagaev et al. have identified four tumor microenvironment (TME) subtypes that are conserved across diverse cancers and correlated with immunotherapy response in melanoma, bladder, and gastric cancers. They provided a visual tool revealing the TME subtypes integrated with targetable genomic alterations, which provided a planetary view of each tumor that can aid in oncology clinical decision making. We aim to use this tool to prospectively analyse the biopsy specimens of osteosarcomas to identify their TME subtypes so as to deliver appropriate treatment strategy if these osteosarcomas experience disease progression afterwards. We will compare the past sequencing date stored in PKUPH bank so as to compare the event-free survival(EFS) of these patients to check the Superiority of this method later.

Interventions

DRUGChemotherapy

Group IE/F: After progression, try LRRC15 ADC + PD-1 inhibitors; Group IE: After progression, try simple anti-PD-1 inhibitors; Group F: After progression, try LRRC15 ADC; Group D: After progression, try B7-H3 ADC or other irrinotecan analogue

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

8 Years to 70 Years

Healthy volunteers

Inclusion criteria

* (i) patients who have been suspected for osteosarcoma with enough clinical or radiographic information; * (ii) patients who have evaluable lesions to resect or follow; * (iii) patients who are planned to be operate with enough flesh specimens for this study.

Exclusion criteria

* (i) clinical information was not complete; * (ii) lost to follow-up.

Design outcomes

Primary

Measure	Time frame	Description
Event-free Survival (EFS)	2 year	From biopsy to progression/last follow-up

Secondary

Measure	Time frame	Description
Event-free Survival (EFS) for the second time	2 year	From first progression to the second progression/last follow-up

Other

Measure	Time frame
Correlation with some DNA target expression	1 year

Contacts

Primary ContactLu Musculoskeletal Tumor Center of PKUPH, M.D.

xielu@pkuph.edu.cn+86-86491437

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026